About SYNERGY A.I.

This startup develops deep-learning software that enhances precision diagnosis and treatment processes in the medical field, specifically targeting autosomal dominant polycystic kidney disease. Their products, including a medical AI development engine and machine learning operations pipelines, provide actionable insights to help prevent the decline of kidney function in patients.

```xml <problem> Diagnosing arrhythmias often relies on infrequent ECG measurements, potentially missing critical events and delaying necessary interventions. Current diagnostic methods can be subjective and may not provide timely predictions of arrhythmia events, leading to potential patient management failures and increased risk of adverse outcomes like stroke or cardiac arrest. The increasing global prevalence of arrhythmias, particularly among the aging population, exacerbates the need for more effective and proactive diagnostic tools. </problem> <solution> Synergy A.I. offers an AI-powered solution for predicting arrhythmia events, enabling earlier and more accurate diagnoses. By leveraging a large dataset of over 3 million records, their technology predicts the likelihood of arrhythmia events with a high degree of accuracy. This predictive capability allows clinicians to proactively manage patients at risk, facilitating timely interventions and potentially preventing severe complications. The AI algorithms analyze ECG data to identify subtle patterns indicative of future arrhythmia events, providing actionable insights for personalized treatment strategies. </solution> <features> - AI-driven prediction of arrhythmia events with 92.7% accuracy, based on a dataset of over 3 million ECG records - Analysis of ECG measurements to identify patients at high risk of developing clinically important arrhythmias (CIA) - Facilitates proactive patient management through early detection and intervention - Supports personalized treatment strategies based on AI-driven insights - Assists in preventing severe side effects associated with missed arrhythmia diagnoses, such as stroke and cardiac arrest - Provides objective, data-driven insights to supplement clinical judgment </features> <target_audience> The primary target audience includes cardiologists, electrophysiologists, and general practitioners seeking to improve arrhythmia diagnosis and management, as well as hospitals and clinics aiming to reduce adverse events related to undiagnosed arrhythmias. </target_audience> ```

What does SYNERGY A.I. do?

Where is SYNERGY A.I. located?

SYNERGY A.I. is based in Seoul, South Korea.

When was SYNERGY A.I. founded?

SYNERGY A.I. was founded in 2018.

How much funding has SYNERGY A.I. raised?

SYNERGY A.I. has raised 560000.

Location

Seoul, South Korea

Founded

2018

Funding

560000

Employees

4 employees

Major Investors

POSTECH Holdings

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

SYNERGY A.I.

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

synergyai.co 100+

Crunchbase

Founded 2018 – Seoul, South Korea

Funding

Estimated Funding

$500K+

Major Investors

POSTECH Holdings

Team (<5)

No team information available.

Company Description

Problem

Diagnosing arrhythmias often relies on infrequent ECG measurements, potentially missing critical events and delaying necessary interventions. Current diagnostic methods can be subjective and may not provide timely predictions of arrhythmia events, leading to potential patient management failures and increased risk of adverse outcomes like stroke or cardiac arrest. The increasing global prevalence of arrhythmias, particularly among the aging population, exacerbates the need for more effective and proactive diagnostic tools.

Solution

Synergy A.I. offers an AI-powered solution for predicting arrhythmia events, enabling earlier and more accurate diagnoses. By leveraging a large dataset of over 3 million records, their technology predicts the likelihood of arrhythmia events with a high degree of accuracy. This predictive capability allows clinicians to proactively manage patients at risk, facilitating timely interventions and potentially preventing severe complications. The AI algorithms analyze ECG data to identify subtle patterns indicative of future arrhythmia events, providing actionable insights for personalized treatment strategies.

Features

AI-driven prediction of arrhythmia events with 92.7% accuracy, based on a dataset of over 3 million ECG records

Analysis of ECG measurements to identify patients at high risk of developing clinically important arrhythmias (CIA)

Facilitates proactive patient management through early detection and intervention

Supports personalized treatment strategies based on AI-driven insights

Assists in preventing severe side effects associated with missed arrhythmia diagnoses, such as stroke and cardiac arrest

Provides objective, data-driven insights to supplement clinical judgment

Target Audience

The primary target audience includes cardiologists, electrophysiologists, and general practitioners seeking to improve arrhythmia diagnosis and management, as well as hospitals and clinics aiming to reduce adverse events related to undiagnosed arrhythmias.